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Abstract
Problem: Enteroviruses are common human viruses associated with various clinical syndromes, from minor febrile
illness to severe, potentially fatal conditions (e.g., aseptic meningitis, paralysis, myocarditis, and neonatal enteroviral
sepsis). Multiple enterovirus serotypes exist. Individual serotypes have different temporal patterns of circulation and
often are associated with different clinical manifestations. Changes in circulating serotypes might be accompanied by
large-scale outbreaks.
Reporting Period Covered: 1970–2005.
Description of Surveillance System: The National Enterovirus Surveillance System (NESS) is a voluntary, passive
surveillance system that has monitored trends in circulating enteroviruses since 1961. Enterovirus detections by sero-
type with specimen type, collection date, and demographic information are reported monthly by participating labora-
tories to CDC, which summarizes the data and disseminates the results. For this analysis, the available data set for
1970–1982 included only information on serotype and state for each report; complete records were available for
1983–2005.
Results: During 1970–2005, a total of 52,812 enterovirus detections were reported to NESS (29,772 of them during
1983–2005). Laboratory participation and the numbers of reports declined throughout the 1990s, but they increased
again after 2000. The 15 most commonly reported enteroviruses accounted for 83.5% of reports with known serotype,
and the five most commonly reported serotypes (echoviruses [E] 9, 11, 30, and 6, and coxsackievirus B5) accounted
for 48.1%. Predominant serotypes and ranking of individual enteroviruses changed over time. Long-term circulation
patterns for individual serotypes varied but were consistent with epidemic (e.g., E9, E13, E30, and coxsackievirus B5)
or endemic patterns (e.g., coxsackieviruses A9, B2, B4, and enterovirus 71). Children aged <1 year accounted for
44.2% of reports with known age. Male predominance was present among patients aged <20 years, but not among
those aged >20 years (male/female ratio: 1.4 and 0.9, respectively). Enterovirus detections had prominent summer-fall
seasonality, with June–October accounting for 77.9% of reports with known month of specimen collection. Cere-
brospinal fluid was the most common specimen type, followed by respiratory and fecal specimens (49.8%, 26.9%, and
13.6%, respectively). Death was reported for 3.3% of detections with known outcome. Infections with coxsackievirus
B4 (odds ratio [OR] = 3.3; 95% confidence interval [CI] = 1.7–6.0), and human parechovirus 1 (formerly E22)
(OR = 3.7; CI = 1.7–7.6) were associated with higher risk for death, and infections with E9 were associated with lower
risk for death (OR = 0.1; CI = 0–0.4) than infections with other enteroviruses.
Interpretation: NESS data allowed identification and description of a core group of consistently circulating enterovi-
ruses that probably determine the disease burden associated with enterovirus infections. These data also are helpful in
guiding outbreak investigations and identifying targets for development of diagnostic assays and antivirals. Efforts to
update the reporting system initiated in the early 2000s (i.e., simplification of reporting forms and transition to
electronic reporting) resulted in a substantial increase in reporting compared with the late 1990s.
Public Health Action: Efforts to increase laboratory participation in NESS should continue to allow for more com-
plete and accurate surveillance for enteroviruses. Further improvement in the timeliness of feedback through the
development of a NESS website to allow access to historic data and to the information on circulating serotypes can
provide additional incentives to public health laboratories to participate in NESS.
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Introduction
Enteroviruses (genus Enterovirus, family Picornaviridae) are
among the most common viruses infecting humans world-
wide. Enteroviruses are associated with diverse clinical syn-
dromes ranging from minor febrile illness to severe, potentially
fatal conditions (e.g., aseptic meningitis, encephalitis, paraly-
sis, myocarditis, and neonatal enteroviral sepsis) and could be
linked with the development of some chronic diseases (e.g.,
type 1 diabetes and dilated cardiomyopathy) (1,2). Each year,
an estimated 10–15 million symptomatic enterovirus infec-
tions occur in the United States (3).
Enteroviruses are small (approximately 30 nm),
nonenveloped, single-stranded RNA viruses with an icosahe-
dral capsid composed of 60 subunits consisting of four struc-
tural proteins (VP1 to VP4). Enterovirus RNA is
approximately 7.5 kb long and encodes a polyprotein that is
processed to yield the mature structural and nonstructural
proteins. The coding region is bounded by nontranslated
regions at the 5’ and 3’ ends (1).
Serotypes of human enteroviruses have traditionally been
classified into echoviruses, coxsackieviruses group A and B,
and polioviruses. This traditional taxonomy was based on the
associated disease in humans and animal model systems, some-
times resulting in overlaps between groups and difficulties with
classification. As a result, beginning in the 1960s, newly dis-
covered enteroviruses receive a numeric designation (e.g.,
enterovirus 71) instead of being assigned to one of the tradi-
tional groups (1,4).
Current taxonomy (4) takes into account molecular and
biologic characteristics and divides human enteroviruses into
four species (human enterovirus [HEV] A, B, C, and D) but
keeps traditional names for individual serotypes. Sixty-eight
serotypes are included in the International Committee on
Taxonomy of Viruses classification (Table 1). The distribu-
tion of enteroviruses by species only partially corresponds to
the groups in the traditional classification. Because molecular
techniques of enterovirus typing are becoming increasingly
available, new enteroviruses continue to be identified, and
enteroviruses 79–101 have been recently described (5–13;
CDC, unpublished data, 2005). Echoviruses 22 and 23 have
been reclassified as a new genus (Parechovirus) in Picornaviridae
and are termed human parechoviruses 1 and 2, respectively
(4,14). Although they belong to genetically and biologically
distinct genera, human parechoviruses and human enterovi-
ruses share many epidemiologic and clinical characteristics (4).
The National Enterovirus Surveillance System (NESS),
initiated in 1961 and known during its early years as the
Enterovirus Surveillance Program (15), is the only data source
for nationwide trends in enterovirus infections in the United
States. Serotype-based enterovirus surveillance in the United
States has five objectives: 1) to help public health practitio-
ners determine long-term patterns of circulation for individual
enteroviruses; 2) to help interpret trends in enteroviral dis-
eases (e.g., aseptic meningitis) by associating them with circu-
lating serotypes, which can be helpful for studying the
association of enteroviruses with clinical manifestations (e.g.,
chronic diseases such as diabetes); 3) to guide outbreak inves-
tigations by enabling linkage of disease clusters with individual
serotypes; 4) to help guide development of new diagnostic
tests and therapies; and 5) to monitor poliovirus detections,
thereby supplementing poliomyelitis surveillance in the United
States.
Enterovirus infections, with the exception of paralytic polio,
are not nationally reportable in the United States. Therefore,
NESS is a voluntary, passive surveillance system. State public
TABLE 1. Classification of enteroviruses*
Traditional taxonomy Current taxonomy
Polioviruses Human Enterovirus A (HEV-A)
PV1-3 CAV2-8, 10, 12, 14, 16; EV71, EV76 EV89, EV90, EV91
Coxsackie A viruses Human Enterovirus B (HEV-B)
CAV1-22, 24 CAV9; CBV1-6; E1-7, 9, 11-21, 24-27, 29-33; EV69, EV73-75, EV77-8, EV79-88, EV100-101
Coxsackie B viruses Human Enterovirus C (HEV-C)
CBV1-6 CAV1, 11, 13, 17, 19-22, 24, PV1-3
Echoviruses Human Enterovirus D (HEV-D)
E1-7, 9, 11-21, 24-27, 29-33 EV68, 70
Numbered enteroviruses
EV68-71
* Enteroviruses 79–101, which are not yet included in the International Committee on Taxonomy of Viruses classification, are shown in italics. The gaps
in numbering result from changes in classification. Since the time of their discovery and initial classification, some serotypes have been found to be
identical to another enterovirus (i.e., coxsackievirus A15 is the same as coxsackievirus A11, coxsackievirus A18 is the same as coxsackievirus A13,
coxsackievirus A23 is the same as echovirus 9, echovirus 8 is the same as echovirus 1, and echovirus 34 is a variant of CVA24). In addition, some
serotypes have been reclassified as members of other picornavirus genera or other virus families. Echovirus 10 is reovirus 1 (genus Orthoreovirus,
family Reoviridae), echovirus 28 is human rhinovirus 1A (genus Rhinovirus, family Picornaviridae), enterovirus 72 is human hepatitis A virus (genus
Hepatovirus, family Picornaviridae), and echoviruses 22 and 23 are now considered human parechoviruses 1 and 2, respectively (genus Parechovirus,
family Picornaviridae).
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health laboratories and certain other diagnostic laboratories
willing to participate report monthly all enterovirus detec-
tions in their laboratories to CDC, which summarizes the data
and disseminates the results.
The surveillance is serotype-specific (i.e., requires reporting
of individual serotypes). In the original system, which oper-
ated during 1961–1968, only total numbers of isolates for
each serotype were reported. Beginning in 1969, the unit of
reporting changed from the isolate to the patient from whom
the virus was isolated, and the states began to report the age,
sex, and clinical information for individual source patients
(15). By the 1990s, reporting of clinical information had
become incomplete as laboratory access to details of patient
information became more limited. As a result, in 2002, the
NESS reporting form was revised to include only basic demo-
graphic data (e.g., age, sex, and state), date of specimen
collection, and specimen type.
Laboratory methods used for enterovirus identification have
changed substantially over time. Initially, enteroviruses were
detected exclusively by viral culture (in vitro or in suckling
mice) and identified by neutralization reaction using inter-
secting pools of type-specific antisera (1). Immunofluorescent
assays using monoclonal antibodies became available for some
enteroviruses in the 1980s (2). In the 1990s, new molecular
methods of enterovirus detection and identification were
introduced. Beginning in the mid-1990s, the panenterovirus-
polymerase chain reaction (PCR) assay, which detects all
enteroviruses but does not allow their differentiation, became
increasingly available and supplanted viral culture in many
diagnostic laboratories (16–19). The molecular method for
enterovirus typing based on sequence of the VP1 gene (which
encodes important type-specific epitopes and, therefore, cor-
relates with serotype) was developed in the late 1990s and is
being used by increasing numbers of laboratories (6–13). To
evaluate the impact of the changes in laboratory methods of
enterovirus detection on enterovirus surveillance, beginning
in 2001, reporting laboratories were asked to provide infor-
mation about the methods used for enterovirus detection and
typing.
Methods
This report presents a descriptive analysis of nonpolio
enterovirus infections reported to NESS during 1970–2005
through passive surveillance. Polioviruses, which are rarely
reported to NESS because of the eradication of indigenous
wild polioviruses in the Americas (20) and cessation of oral
poliovaccine use in 2000 (21), are excluded from this analy-
sis. Parechoviruses are included because they continue to be
reported to NESS even after their reclassification. References
to “enteroviruses” as a group throughout the report include
parechoviruses.
The available computerized data set for 1970–1982 con-
tained the information on enterovirus serotypes and the
reporting state only. The analysis of outcome is limited to
1983–1998 because none of the participating laboratories
reported outcome after 1998, probably because of the lack of
access to this information. Therefore, the analysis of overall
trends includes the entire study period, but the descriptive
epidemiologic analysis is limited to 1983–2005, the period
for which complete information is available. The numbers
presented might be slightly different from the previously
reported data because, for this analysis, the identified dupli-
cate reports have been deleted and the records with obvious
errors (e.g., use of nonexisting codes for serotype designation)
were recoded as “unknown.” Analyses were performed using
the data available from laboratory reports, which inherently
reflect the testing practices of the individual laboratories.
Therefore, these data are not representative of population rates
nor are they strictly comparable between laboratories.
A descriptive analysis was conducted of reported enterovi-
rus isolations for the entire 36-year period and for three 10-year
(1970–1979, 1980–1989, and 1990–1999) and one 6-year
(2000–2005) period by month of specimen collection; speci-
men type; patient age, sex, and outcome; and assessed trends
in the number of reporting states and the impact of changing
laboratory practices. In addition, long-term temporal trends
were analyzed to identify patterns of circulation for individual
serotypes. Fifteen enteroviruses most commonly reported dur-
ing the study period and certain less-common viruses of par-
ticular interest because of their virologic or epidemiologic
characteristics or disease associations (coxsackieviruses A16
and 24, echovirus 13, enteroviruses 68 and 71, and human
parechoviruses 1 and 2) are described individually.
Results
During 1970–2005, a total of 52,812 nonpolio enterovirus
detections were reported to CDC; of these, 29,772 detections
were reported during 1983–2005. On average, 1,467 reports
were submitted annually. The annual number of reports var-
ied widely, from 388 in 1999 to 3,460 in 1972. The average
annual number of reported detections was highest in the 1980s
(1,814; range: 1,224–2,221) and lowest during the 1990s
(1,012; range: 343–2,072). The annual number of states and
territories with enterovirus reports also varied substantially,
from 11 in 1999 to 47 in 2004 (Figure 1). The number of
reporting laboratories increased from a low of 11 in 1999, to
24 and 27 during 2000 and 2001, but then declined to 18–
19 during subsequent years. In 2001, three laboratories used
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genomic methods for enterovirus identification and typing.
By 2005, this number had increased to seven.
Enterovirus detections had remarkable seasonality. Cases
increased sharply during summer and fall months with a peak
in August (5,601 [22.3%] of 25,076 reports with known
month during 1983–2005) (Figure 2). For 19,531 (77.9%)
reports, specimens were collected during June–October. This
summer-fall seasonality was more prominent for enterovirus
detections from cerebrospinal fluid (CSF) specimens (81.3%
[7,787 of 9,583] reports during June–October) than for
reports with fecal (77.6% [2,043 of 2,633 reports]) (Chi-
square: p<10-4) or respiratory specimens (69.8% [3,684 of
5,275 reports]) (Chi-square: p<10-6) as the source of detection.
Age was indicated for 25,114 (84.4%) cases. Infants aged
<1 year accounted for 11,095 cases (44.2% of all reports with
known age), children aged 1–4 years for 3,763 cases (15.0%),
aged 5–9 years for 2,911 cases (11.6%), and aged 10–19 years
for 2,996 cases (11.9%) cases. In 4,349 (17.3%) cases, en-
teroviruses were detected from persons aged >20 years. Sex
was reported in 26,812 cases (90.1% of all reports during
1983–2005). Males accounted for 15,294 reports (57.0% of
reports with known sex), and females accounted for 11,518
(43.0%) reports (male/female ratio: 1.3). When stratified by
age, the male predominance was present only among persons
aged <20 years (male/female ratio: 1.4). The male/female ra-
tio among persons aged >20 years was 0.9.
Specimen type was known for 22,579 (75.8%) of 29,772
reports during 1983–2005. CSF was the most common speci-
men, with 11,248 reports (49.8% of reports with known speci-
men type), followed by respiratory specimens (6,068 [26.9%])
and stool/rectal swab (3,078 [13.6%]). Other specimen types
accounted for 2,185 (9.7%) reports.
Outcome was reported for 3,932 (15.9%) of 24,654 cases
during 1983–1998 and was not reported after 1998. During
this reporting period, 131 (3.3%) patients died. Of the 115
deaths with known age, 77 (67.0%) occurred among children
aged <1 year. The proportion of reports with fatal outcome
had a bimodal distribution by age, with the peaks for ages
<1 year and >45 years (Figure 3).
Enterovirus serotype was specified for 49,637 (94.0%)
reports. The proportion of reports with unknown serotype
ranged from very low (0.2% in 1974) to very high (21.1% in
2002). The proportion of reports with unknown serotype
increased substantially during 1997–2002 (range: 15.0%–
21.1%) but declined again after 2002 (Figure 1).
During 1970–2005, a total of 56 enterovirus serotypes and
two parechoviruses were reported (Table 2). Of these, the 15
most commonly reported serotypes accounted for 83.5% of
all reports. The five most common serotypes (echoviruses 9,
11, 30, and 6, and coxsackievirus B5) accounted for approxi-
mately half of all reports (48.1%).
The most commonly reported serotypes changed over time,
as did the ranking of individual serotypes (Table 2). Some
serotypes appeared consistently among those most commonly
reported, and others were reported frequently for a period of
time but were less common at other times. Thirty-six sero-
types appeared among the 15 most commonly reported
enteroviruses for at least 1 year during the study period, 26
serotypes appeared among the top five, and 11 serotypes were
reported as the most common enterovirus for a given year.
Along with the five most common enteroviruses, the 11
serotypes include coxsackieviruses A9 and B2, and
echoviruses 3, 7, 13, and 16.
Long-term trends of circulation of individual enterovirus
serotypes were consistent with two major patterns: epidemic
and endemic. Serotypes with an epidemic pattern of circula-
tion were characterized by substantial fluctuations in circula-
tion levels over time, including large peaks when the serotype
was among the most prevalent enteroviruses reported for a
given year. Serotypes with an endemic pattern had stable and
usually low-levels of circulation with few distinct peaks. The
results of the serotype-specific descriptive analysis by sex, age
group, specimen type and collection month, and outcome




Increases in echovirus 9 activity often are accompanied by
widespread, large-scale outbreaks (22–27). In the United
States, peaks in nationwide hospitalization rates for aseptic
meningitis have been observed for years when echovirus 9 was
predominant (28). The most commonly reported clinical syn-
drome associated with echovirus 9 infection is aseptic menin-
gitis, but paralysis, encephalitis, and severe infections of
neonates and immunodeficient persons also have been reported
(29–32).
Echovirus 9 was the most commonly reported enterovirus
in the United States during 1970–2005, accounting for 11.8%
of reports with known serotype (Table 2). Echovirus 9 has a
distinct epidemic pattern of circulation, with regular sharp
increases in reports every 3–5 years (Figure 4). The virus con-
sistently appeared among the most commonly reported sero-
types (Table 2) and was the most commonly identified
enterovirus six times (1975, 1978, 1984, 1988, 1995, and
2003). Most often, echovirus 9 detections were reported among
persons aged 5–19 years. The source of detection in two thirds
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TABLE 2. Frequencies, ranks, and number of years reported for individual enterovirus serotypes — National Enterovirus
Surveillance System, United States, 1970–2005*
No. of years
 the serotype was
Among Among
Reports with known the the
Overall serotype (N = 49,637) Rank Highest 15 most five most
Serotype rank No. % 1970–1979 1980–1989 1990–1999 2000–2005 rank Reported common common
Echovirus 9 1 5,868 11.8 1 2 4 1 1 36 35 22
Echovirus 11 2 5,638 11.4 2 1 2 10 1 36 35 22
Echovirus 30 3 5,021 10.1 12 3 1 2 1 36 30 18
Coxsackievirus B5 4 4,313 8.7 3 4 9 5 1 36 28 12
Echovirus 6 5 3,023 6.1 5 5 4 6 1 36 34 7
Coxsackievirus B2 6 2,596 5.2 6 6 5 12 1 36 35 14
Coxsackievirus A9 7 2,399 4.8 8 8 6 7 2 36 35 17
Echovirus 4 8 2,304 4.6 4 11 19 14 1 36 27 8
Coxsackievirus B4 9 2,089 4.2 7 9 10 11 2 36 33 10
Echovirus 7 10 2,010 4.0 9 10 7 9 1 35 22 20
Coxsackievirus B3 11 1,945 3.9 10 7 11 13 2 36 32 6
Echovirus 18 12 1,341 2.7 18 13 15 3 2 36 18 6
Coxsackievirus B1 13 1,143 2.3 14 8 8 8 2 35 17 6
Echovirus 3 14 958 1.9 11 16 20 20 1 32 9 8
Echovirus 5 15 916 1.8 22 12 13 18 4 34 21 18
Human Parechovirus 1 16 880 1.8 15 14 14 19 8 35 26 —
Echovirus 14 17 713 1.4 13 19 18 22 4 34 19 1
Coxsackievirus A16 18 615 1.2 17 17 22 21 6 34 11 —
Echovirus 13 19 578 1.2 36 35–36 39 4 1 28 6 2
Echovirus 25 20 547 1.1 19 23 12 16 5 36 16 1
Echovirus 24 21 537 1.1 23 15 26–27 29 5 31 5 1
Echovirus 16 22 501 1.0 16 24 17 25 1 33 6 2
Echovirus 21 23 458 0.9 26 21 25 24 2 31 7 1
Echovirus 20 24 349 0.7 40 20 21 30–34 3 24 2 1
Echovirus 31 25 337 0.7 25 22 24 30–34 9 30 4 —
Echovirus 17 26 286 0.6 27 17 23 46–47 2 27 4 1
Enterovirus 71 27 270 0.5 — 30 16 15 5 23 11 1
Echovirus 2 28 211 0.4 21 28 28 44–45 12 29 2 —
Coxsackievirus A4 29–30 180 0.4 24 31 33 30–34 14 25 2 —
Echovirus 1 29–30 180 0.4 29 26 29 35 17 28 — —
Echovirus 33 31 146 0.3 20 46–47 42 36 3 18 1 1
Coxsackievirus A10 32–33 138 0.3 30 29 30 37–39 14 27 2 —
Echovirus 27 32–33 138 0.3 35 27 26–27 30–34 16 30 — —
Echovirus 15 34–35 120 0.2 33 32 31–32 27–28 18 31 — —
Echovirus 19 34–35 120 0.2 28 44 36 27–28 12 24 1 —
Coxsackievirus A2 36 87 0.2 31 35–36 40–41 44–45 18 19 — —
Coxsackievirus A5 37 72 0.1 32 38–39 48–51 37–39 12 20 1 —
Coxsackievirus B6 38 68 0.1 48 33 31–32 37–39 18 24 — —
Human Parechovirus 2 39 60 0.1 39 37 34 40 17 22 — —
Coxsackievirus A6 40 58 0.1 38 34 43–45 — 17 15 — —
Coxsackievirus A24 41 55 0.1 49 53–54 52–56 17 6 8 1 —
Echovirus 12 42 53 0.1 37 40 35 41–43 20 23 — —
Coxsackievirus A7 43 46 0.1 34 41 52–56 41–43 20 15 — —
Coxsackievirus A21 44 42 0.1 44–47 38–39 37–38 30–34 17 17 — —
Coxsackievirus A13 45 32 0.1 41 42–43 43–45 — 19 11 — —
Echovirus 29 46 27 0.1 44–47 45 37–38 — 26 14 — —
Enterovirus 68 47 26 0.1 — 55–57 40–41 23 15 9 1 —
Echovirus 32 48 25 0.1 42 46–47 48–51 — 27 14 — —
Coxsackievirus A1 49 24 <0.1 44–47 55–57 48–51 26 11 7 1 —
Coxsackievirus A14 50 21 <0.1 54 42–43 48–51 41–43 21 8 — —
Coxsackievirus A8 51 17 <0.1 43 49 52–56 — 24 10 — —
Echovirus 26 52 16 <0.1 52 48 43–45 — 33 9 — —
Coxsackievirus A3 53 13 <0.1 44–47 50–52 46–47 — 31 9 — —
Coxsackievirus A11 54 10 <0.1 51 50–52 46–47 — 31 8 — —
Coxsackievirus A17 55 8 <0.1 50 53–54 52–56 — 36 7 — —
Coxsackievirus A20 56 5 <0.1 — 50–52 — 46–47 27 3 — —
Coxsackievirus A12 57 3 <0.1 53 55–57 — — 37 2 — —
Enterovirus 70 58 1 <0.1 — — 52–56 — 26 1 — —
* The 15 most common serotypes are shown in bold. Coxsackieviruses A19 and A22, enterovirus 69, and recently identified enteroviruses numbered 73
and higher have not been reported during the study period.
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of reports was CSF. Fatal outcome was rarely reported (0.2%),
and persons infected with echovirus 9 were at a significantly
lower risk for death than persons infected with other sero-
types (odds ratio [OR] = 0.1; 95% confidence interval [CI] =
0–0.4).
Echovirus 11
The most serious, potentially fatal clinical presentation
associated with echovirus 11 is neonatal systemic illness, pre-
senting as hepatitis-hemorrhage syndrome (33–36). Echovi-
rus 11 has been associated with numerous limited outbreaks
in neonatal nurseries (34,36). Aseptic meningitis is a com-
mon presentation, but unlike other common enteroviruses,
echovirus 11 has rarely been associated with community out-
breaks of meningitis (35,37,38). Echovirus 11, the second most
commonly identified enterovirus during the study period,
accounted for 11.4% of reports with known serotype (Table 2).
Echovirus 11 has an epidemic pattern of circulation; increases
in reports occur with irregular intervals and usually last for
several years (Figure 5). The overall level of echovirus 11 cir-
culation was highest during 1979–1992, when it was the most
commonly reported enterovirus six times (1979, 1980, 1982,
1985, 1986, and 1992). The virus has been relatively quies-
cent since then, with the exception of a sharp increase in 1999,
when it was the most commonly reported enterovirus. The
majority of echovirus 11 detections during the study period
were made in infants aged <1 year, and CSF was the most
common specimen. Death of a patient was reported for 4.6%
of echovirus 11 detections with known outcome (Table 3).
Echovirus 30
Aseptic meningitis is the most commonly reported syndrome
associated with echovirus 30 (39–45). Meningoencephalitis
and milder illnesses (e.g., respiratory illnesses and herpangina)
also occur (43,44). Increases in echovirus 30 activity are char-
acterized by global spread and large-scale aseptic meningitis
outbreaks (22,26,37,39–45). Waves of echovirus 30 activity
are associated with distinct new genomic lineages, which usu-
ally replace previously circulating ones (46–48). Echovirus 30
was the third most commonly identified enterovirus during
the study period and accounted for 10.1% of reports with
known serotype (Table 2). Echovirus 30 has an epidemic
TABLE 3. Reports of selected enteroviruses, by sex and age of source patient, specimen type and collection month, and outcome —




Specimen type No. with
Sex Age groups (yrs) Most No. with known Outcome*
No. with No. with common known June– specimen No. with
% known % known specimen specimen Oct collection % known
Selected serotypes  Male sex <1 1–4 5–19 >20 age Type % type % month Fatal outcome
Echovirus 9† 57.9 2,837 29.9 13.5 36.9 19.7 2,653 CSF§ 67.5 2,627 75.5 2,810 0.2 405
Echovirus 11 57.8 2,541 54.8 15.6 13.2 16.3 2,327 CSF 42.4 2,136 75.1 2,437 4.6 435
Echovirus 30 56.3 3,265 22.3 10.9 42.6 24.2 3,068 CSF 73.8 3,010 78.6 3,287 3.2 310
Coxsackievirus B5 55.3 2,041 49.2 14.9 16.8 19.1 1,844 CSF 47.1 1,634 83.4 1,790 1.5 325
Echovirus 6 57.1 1,520 41.9 14.6 24.9 18.5 1,414 CSF 52.0 1,284 80.5 1,379 5.9 185
Coxsackievirus B2 59.1 1,293 63.4 14.2 11.4 11.0 1,157 CSF 39.2 1,089 79.1 1,188 3.8 263
Coxsackievirus A9 56.8 1,257 39.4 16.6 26.5 17.5 1,126 CSF 54.4 1,048 80.9 1,176 1.7 346
Echovirus 4 54.9 687 27.6 12.9 36.1 23.4 595 CSF 65.0 535 80.0 636 2.8 72
Coxsackievirus B4 56.2 937 62.5 15.5 9.6 12.4 865 CSF 41.1 755 81.7 861 9.8 123
Echovirus 7 57.2 1,139 57.0 17.0 14.1 11.9 1,055 CSF 44.2 952 76.5 1,214 2.5 203
Coxsackievirus B3 56.6 830 63.7 14.9 12.3 9.1 766 Resp 38.6 664 78.3 787 5.4 130
Echovirus 18 57.2 934 41.4 12.6 27.6 18.3 927 CSF 54.0 752 79.7 661 1.8 57
Coxsackievirus B1 52.5 676 67.9 11.2 10.1 10.8 651 Resp 39.9 576 81.1 673 0 104
Echovirus 3 61.5 174 54.7 23.6 13.7 8.1 161 Resp 38.8 129 79.7 182 NA¶ 15
Echovirus 5 57.8 457 46.4 10.9 22.6 20.1 412 CSF 44.9 352 74.6 453 3.8 80
Coxsackievirus A16 54.4 259 28.3 41.3 16.1 14.3 223 Other 41.2 199 68.3 252 1.1 92
Coxsackievirus A24 56.0 25 3.6 3.6 39.3 53.6 28 Other 98.0 49 97.9 48 NA 0
Echovirus 13 59.2 397 44.9 11.0 31.5 12.6 390 CSF 54.1 392 62.4 93 NA 1
Enterovirus 68 59.1 22 29.4 35.3 11.8 23.5 17 Resp 95.7 23 50.0 24 NA 1
Enterovirus 71 58.7 223 42.1 30.7 11.9 15.3 202 Resp 40.2 174 70.5 237 NA 15
Human Parechovirus 1 58.6 495 73.0 22.6 2.0 2.4 456 Resp 45.2 321 62.9 474 10.9 92
Human parechovirus 2 55.9 34 67.6 20.6 0 11.8 34 Resp 50.0 18 54.5 33 NA 8
* Outcome information was available for 1983–1998.
† The 15 most common serotypes are shown in bold and are listed according to their overall ranking; other serotypes are presented alphabetically.
§ CSF: cerebrospinal fluid; Resp: respiratory specimens.
¶ <50 observations or outcome information not available.
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pattern of circulation. During the study period, increases in
reported activity occurred with irregular intervals and lasted
for few years (Figure 6). During the early years of the study
period, echovirus 30 was rarely reported. Four major waves of
increased activity occurred after 1975 (1975–1985, 1990–
1993, 1997–1998, and 2003–2005). The virus consistently
appeared among the most commonly reported enteroviruses
(Table 2) and was the most commonly identified enterovirus
seven times (1981,1990,1991,1993,1997,1998, and 2004).
Echovirus 30 was more commonly detected from older chil-
dren and adults (66.8%) than from young children, with only
33.2% of reports among persons aged <5 years. CSF was the
source for approximately three fourths of echovirus 30 detec-
tions (Table 3).
Coxsackievirus B5
The major clinical presentations of coxsackievirus B5
infections are similar to those observed for other group B
coxsackieviruses and include myopericarditis and neonatal
systemic illness (encephalomyocarditis syndrome), aseptic
meningitis, meningoencephalitis, and acute flaccid paralysis.
Hand, foot, and mouth disease and herpangina also have been
reported, and a potential association with development of type
1 diabetes has been suggested (41,49–56). Outbreaks, mostly
of aseptic meningitis, are common in epidemic years
(50,54,55). Coxsackievirus B5, the fourth most commonly
identified enterovirus during the study period, accounted for
8.7% of reports with known serotype during 1970–2005
(Table 2). Coxsackievirus B5 has a distinct epidemic pattern
of circulation with regular sharp increases every 3–6 years,
which usually last for 1 year (Figure 7). The extent of the
increase in activity varied, and smaller peaks sometimes were
observed between major ones. Throughout the study period,
coxsackievirus B5 consistently appeared among the most com-
monly reported enteroviruses (Table 2) and was the most com-
monly identified enterovirus seven times (1972, 1973, 1983,
1989, 1996, 2000, and 2005). Approximately half of all
coxsackievirus B5 detections came from young infants, and
CSF was the most common source. The summer-fall season-
ality in coxsackievirus B5 detections was more prominent than
for most other serotypes (Table 3).
Echovirus 6
During its high activity periods, echovirus 6 often is associ-
ated with outbreaks, such as community outbreaks of aseptic
meningitis or nursery outbreaks among neonates (27,21,57–
60). Reported clinical presentations include aseptic meningi-
tis, meningoencephalitis, rashes, and gastrointestinal illnesses.
Neonatal echovirus 6 infections can be associated with hepa-
titis and pneumonitis (57–63). Echovirus 6 was the fifth most
commonly identified enterovirus during the study period and
accounted for 6.2% of reports with known serotype (Table 2).
Echovirus 6 has an epidemic pattern of circulation reminis-
cent of that for echoviruses 11 and 30 (Figure 8), with three
major waves of activity (1970–1977, 1985–1990, and 1994–
2000) and an increase in 2005. Although echovirus 6 consis-
tently appeared among the most commonly reported
enteroviruses (Table 2), it was the most commonly reported
serotype only in 1977. Children aged <1 year were the most
common source of echovirus 6 detection, CSF was the most
common specimen accounting for more than 50% of reports,
and 5.6% of detections with known outcome resulted in death
(Table 3).
Coxsackievirus B2
Clinical illnesses associated with coxsackievirus B2 include
aseptic meningitis, myocarditis, and neonatal systemic illness
(38,51,64,65). Outbreaks in settings such as football teams
and summer camps have been reported (64,66), but wide-
spread community outbreaks are not typical. Coxsackievirus
B2 accounted for 5.2% of reports with known serotype dur-
ing 1970–2005 (Table 2). The virus has an endemic pattern
of circulation with year-to-year variability (Figure 9) and has
consistently appeared among the top 15 serotypes. Two epi-
sodes of unusually high activity of coxsackievirus B2 have been
document: in 1976 and 1994, when it became the most com-
monly reported enterovirus, accounting for >15% of all
reported enteroviruses. The proportion of children aged <1 year
among reports of coxsackievirus B2 detections exceeded 60%,
and CSF was the most common source of detection (Table 3).
Coxsackievirus A9
Neurologic illnesses (e.g., aseptic meningitis, meningoen-
cephalitis, and encephalitis), including cases occurring in the
context of hand, foot, and mouth disease outbreaks, and epi-
demic neuropathy predominate among clinical manifestations
of coxsackievirus A9 infection (38,67,68). In addition to spo-
radic detection, a community outbreak has been reported (69).
Coxsackievirus A9 accounted for 4.8% of reports with known
serotype reported to NESS during 1970–2005 (Table 2). Al-
though coxsackievirus A9 consistently appeared among the
most commonly reported enteroviruses, its highest rank dur-
ing the study period was second in 1973, when it accounted
for approximately 12% of all reports. Coxsackievirus A9 is a
typical representative of enteroviruses with an endemic pat-
tern of circulation (Figure 10). Children aged <1 year were
the most common age group for coxsackievirus A9 detection,
and CSF was the most common specimen. Death occurred in
1.7% of reports with known outcome (Table 3).
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Echovirus 4
Outbreaks of aseptic meningitis caused by echovirus 4 have
been described in several countries (26,70–72). A new
genetic variant of echovirus 4, which has replaced previously
circulating lineages, might have been circulating since 1997
(70). Echovirus 4 accounted for 4.6% of reports with known
serotype (Table 2). Echovirus 4 has a cyclical, epidemic pat-
tern of circulation with irregular intervals between periods of
high activity. The highest level of activity was observed dur-
ing 1970–1978 (in 1973, it was the most commonly identi-
fied enterovirus, accounting for >30% of all reports), and
during 1984–1990, with a minor peak during 2001–2002
(Figure 11). The virus was frequently present among the 15
most common enteroviruses, but its ranking declined from
fourth during the 1970s to 19th during the 1990s (Table 2).
In 36.1% of reports, echovirus 4 was detected among persons
aged 5–19 years. Children aged <5 years accounted for <50%
of all echovirus 4 reports. CSF was the source of echovirus 4
in approximately two thirds of reports (Table 3).
Coxsackievirus B4
Outbreaks of coxsackievirus B4 are rare. Most common clini-
cal syndromes associated with coxsackievirus B4 include aseptic
meningitis, encephalitis, myopericarditis, neonatal infections,
febrile rash illnesses, and respiratory manifestations (73–75).
Coxsackievirus B4 accounted for 4.2% of reports with known
serotypes and has consistently appeared among the 15 most
common enteroviruses, but it has never been the predomi-
nant serotype (Table 2). Coxsackievirus B4 has an endemic
pattern of circulation (Figure 12). Approximately 60% of all
coxsackievirus B4 detections came from young infants, and
CSF was the most common source. Similar to coxsackievirus
B5, the summer-fall seasonality in coxsackievirus B4 detec-
tions was more prominent than for the majority of other sero-
types. Coxsackievirus B4 had one of the highest proportions
of reports with fatal outcome (9.8%) (Table 3), with a signifi-
cantly higher risk of death when compared with fatal out-
comes among persons infected with any other enterovirus
serotypes (OR = 3.3; CI = 1.7–6.4).
Echovirus 7
Clinical presentations of echovirus 7 infection include aseptic
meningitis, meningoencephalitis, paralysis, gastrointestinal
manifestations, and neonatal systemic illness. Outbreaks
associated with echovirus 7 have been rarely reported (76–80).
Echovirus 7 accounted for 4.0% of reports with known sero-
type during 1970–2005 (Table 2). Echovirus 7 has a cyclical,
epidemic pattern of circulation with irregular intervals between
periods of high activity. Echovirus 7 commonly appeared
among the 15 most common enteroviruses and was the most
commonly reported serotype in 2002. The increased activity
of echovirus 7 was reported during 1978–1979, 1985–1987,
1991–1997, and 2002 (Figure 13). In approximately 60% of
reports, echovirus 7 was detected in young infants. CSF was
the most common source of echovirus 7 detections (Table 3).
Coxsackievirus B3
Coxsackievirus B3 has been commonly associated with
myopericarditis, aseptic meningitis, neonatal systemic illness,
meningoencephalitis in immunodeficient persons, herpangina,
and rash illnesses (81–83). Outbreaks of neonatal infections
and herpangina and a cluster of myocarditis cases in the con-
text of community wide coxsackievirus B3 outbreak have been
reported (84–86). Coxsackievirus B3 accounted for 3.9% of
reports with known serotype (Table 2). Coxsackievirus B3 has
an epidemic pattern of circulation. The increases in its activ-
ity are of variable duration and extent and occur after variable
periods of quiescence (Figure 14). Coxsackievirus B3 has con-
sistently appeared among the 15 most commonly reported
enteroviruses but has never been the most commonly reported
virus, with a highest ranking of second in 1980 and 1994.
The proportion of children aged <1 year among reports of
coxsackievirus B3 detections exceeded 60%, and respiratory
specimens were the most common source of detection. Fatal
outcome was reported for 5.4% of coxsackievirus B3 detec-
tions with known outcome (Table 3).
Echovirus 18
Outbreaks associated with echovirus 18 have been reported
during the periods of its increased circulation. The most com-
monly reported clinical syndrome associated with echovirus
18 infection is aseptic meningitis, but paralysis, neonatal sep-
sis, and other manifestations also have been documented
(40,87–89). Echovirus 18 accounted for 2.7% of reports with
known serotype (Table 2). The virus has an epidemic pattern
of circulation with increased levels of activity after prolonged
quiescence. During 1970–2005, two periods of increased
activity of echovirus 18 were observed (1986–1987 and 1995–
2005) (Figure 15). Activity reached its highest level in 2001.
Echovirus 18 appeared among the 15 most common enterovi-
ruses during 18 of 36 years of the study period; it has never
been the predominant enterovirus, but ranked second in 1987
and 2001. Children aged <1 year were the most common age
group for echovirus 18 detection, and CSF was the most com-
mon specimen. Death was reported for 1.8% of echovirus 18
cases with known outcome (Table 3).
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Coxsackievirus B1
Coxsackievirus B1 has been associated with outbreaks of
aseptic meningitis and pleurodynia (35,90–92). Common
clinical presentations are similar to other group B
coxsackieviruses and include aseptic meningitis, meningoen-
cephalitis, myocarditis, hand, foot, and mouth disease, and
pleurodynia. Coxsackievirus B1 also can cause systemic neo-
natal illness sometimes presenting as fulminant hepatitis with
coagulopathy, a syndrome usually associated with echovirus
11 rather than with encephalomyocarditis syndrome typical
for coxsackieviruses B2-5 (33,92). Coxsackievirus B1
accounted for 2.3% of reports with known serotype during
1970–2005 (Table 2). Coxsackievirus B1 has an epidemic
pattern of circulation, with increased activity occurring with
irregular intervals and usually lasting several years (Figure 16).
The overall level of coxsackievirus B1 circulation showed a
tendency toward increase since the 1990s. Coxsackievirus B1
appeared among the 15 most common enteroviruses during
17 of 36 years of the study period; it has never been the most
commonly reported enterovirus but ranked second in 1977.
Two thirds of coxsackievirus B1 reports during the study
period were from infants aged <1 year, and respiratory speci-
mens were the most common source of its detection. No fatal
outcomes were reported for 104 coxsackievirus B1 detections
with known outcome. Similar to coxsackieviruses B4 and B5,
the summer-fall seasonality in coxsackievirus B1 detections
was more prominent than for the majority of other serotypes
(Table 3). Reports of coxsackievirus B1 had the least promi-
nent male predominance of all serotypes (52.5%).
Echovirus 3
An echovirus 3 aseptic meningitis outbreak was reported in
the early 1970s, but few cases were reported in subsequent
years (93). Other reported clinical syndromes include menin-
goencephalitis and paralysis (94,95). Although echovirus 3
remains rare in the United States, an outbreak was reported in
South Africa in 2001 (96). Echovirus 3 accounted for 1.9%
of reports with known serotype (Table 2). The virus has a
distinct epidemic pattern of circulation with regular
increases every 4–7 years (Figure 17). Echovirus 3 was the
most commonly detected enterovirus in 1970, but since then,
the magnitude of periodic increases has been declining. After
the mid-1990s, the serotype has become very uncommon. The
majority of echovirus 3 reports were identified in infants
aged <1 year, and respiratory specimens were the most
common source of its detection (Table 3).
Echovirus 5
A small outbreak of echovirus 5 aseptic meningitis occurred
among adults in Finland in 1985, concurrent with the last
reported increase of this virus in the United States (97). Dur-
ing 1970–2005, echovirus 5 accounted for 1.8% of reports
with known serotype (Table 2). Echovirus 5 has an epidemic
pattern of circulation, with increased activity occurring with
irregular intervals and usually lasting several years (Figure 18).
Echovirus 5 frequently appeared among the 15 most com-
mon enteroviruses with a high rank of fourth in 1982. After
1990, the magnitude of periodic increases in its activity
declined considerably. Children aged <1 year were the most
common source for echovirus 5 detection, and CSF was the
most common specimen. Fatal outcome was reported in 3.8%
of echovirus 5 infections with known outcome (Table 3).
Echovirus 13
During the approximately 50 years after its initial identifi-
cation, echovirus 13 remained rare, with no reports of out-
breaks associated with this virus. However, a worldwide spread
of the virus occurred during 2000–2001 and caused major
outbreaks of aseptic meningitis throughout the world (57,98–
103). Genetically, the majority of echovirus 13 isolates have
diverged considerably from the prototype strain, but all cir-
culating strains are closely related (98). Clinical presentations
associated with echovirus 13 include aseptic meningitis,
encephalitis, respiratory and gastrointestinal manifestations,
and chronic infection of immunodeficient hosts (98,104,105).
During 1970–2005, echovirus 13 accounted for 1.2% of
reports with known serotype (Table 2). A slight increase oc-
curred in 2000 (12 reports), followed by a sharp peak of 412
reports in 2001, when it became the most commonly identi-
fied enterovirus in the United States (Figure 19). Since then,
the levels of echovirus 13 activity have declined, but the virus
continues to appear among the 15 most common serotypes.
Children aged <1 year were the most common age group for
echovirus 13 reports, and CSF was the most common speci-
men. Echovirus 13 had less prominent summer-fall seasonal-
ity than other enteroviruses, with only 62.4% of reports during
June–October (Table 3).
Coxsackievirus A16
The most common illness associated with coxsackievirus
A16 infection is hand, foot, and mouth disease. More serious
manifestations are rare, but cases of aseptic meningitis, fatal
myocarditis, rhabdomyolysis with renal failure, and neonatal
febrile illness have been described, and outbreaks have been
reported (106–110). During 1970–2005, coxsackievirus A16
accounted for 1.2% of reports with known serotype (Table 2).
The virus rarely appeared among the 15 most common
enteroviruses and never ranked higher than sixth.
Coxsackievirus A16 has an endemic pattern of circulation
(Figure 20). The reported overall levels of coxsackievirus A16
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activity were higher during the 1970s and 1980s and have
declined since 1990. The age group most commonly associ-
ated with coxsackievirus A16 detections was children aged 1–4
years, and specimens coded as “other” were the most frequent
source, possibly referring to scrapings from hand, foot, and
mouth disease lesions. The summer-fall seasonality was present,
but to a somewhat lesser extent than for other enteroviruses.
Death was reported for 1.1% of coxsackievirus A16 infec-
tions in persons with known outcome (Table 3).
Coxsackievirus A24
Coxsackievirus A24 variant is one of the two enteroviruses,
along with enterovirus 70, associated with massive outbreaks
of acute hemorrhagic conjunctivitis, which periodically occur
in tropical areas and involve large populations (111,112).
Coxsackievirus A24 was rarely reported during the study
period (Table 2). Of 55 reports, 45 (81.8%) were associated
with a single outbreak of acute hemorrhagic conjunctivitis in
Puerto Rico (112). Approximately half of detections were from
adults, all but one specimen were coded as “other” (presumably,
conjunctival swabs), and nearly all of the reported infections
occurred during the summer-fall period.
Enterovirus 68
Enterovirus 68 is unique among the enteroviruses because
it has properties of both enteroviruses and rhinoviruses (mem-
bers of another genus in the Picornaviridae family). Strains
of enterovirus 68 have been independently identified as
rhinovirus 87, but recent genomic sequence data for both
viruses confirmed that they are of the same type (113,114).
Enterovirus 68 is one of the most rarely reported serotypes,
with only 26 reports throughout the 36-year study period
(Table 2). The first report of enterovirus 68 to NESS was in
1987, and the highest number of reports in a single year was
11 in 2003. This increase was largely associated with enhanced
detection at the site of a study of respiratory viruses among
asthma patients (113). In all but one case, enterovirus 68
was detected from respiratory specimens, and in one case in
2005 from CSF of a patient with acute flaccid paralysis. This
case, in a young adult, was the first report of CNS infection
by enterovirus 68. The most common age group associated
with enterovirus 68 was children aged 1–4 years, but approxi-
mately one fourth of all reports were in adults aged >20 years.
Fifty percent of all reported enterovirus 68 infections
occurred outside the typical summer-fall season (Table 3).
Enterovirus 71
Enterovirus 71 is associated with serious neurologic mani-
festations (e.g., aseptic meningitis, polio-like paralysis, and
bulbar encephalitis) and mild rashes, including hand, foot,
and mouth disease. Outbreaks of paralysis were reported in
Europe during the 1960s and 1970s (115). During the late
1990s and early 2000s, outbreaks of fatal bulbar encephalitis
among young children occurred in the southeast Asian coun-
tries, usually in the context of enterovirus 71-associated out-
breaks of hand, foot, and mouth disease (116–119). Localized
outbreaks of enterovirus 71-associated illnesses have been docu-
mented in the United States since 1973 (115), but no detec-
tions were reported to NESS until 1983. During 1983–2005,
a total of 270 cases of enterovirus 71 were reported (Table 2).
The overall temporal pattern of enterovirus 71 reports was
consistent with endemic circulation (Figure 21). An increas-
ing trend in overall level of reported activity was documented,
especially after the mid-1990s, but large-scale nationwide
activity, similar to the ones in southeast Asia in the late 1990s
and early 2000s, has not been observed. Enterovirus 71 was
reported during 23 of the 36 study years, and it appeared
among the 15 most common serotypes 11 times (1987, 1994,
and 1996–2005), with a high ranking of fifth in 1994. Chil-
dren aged <1 year were the most common source of enterovi-
rus 71 reports; children aged <5 years accounted for
approximately three fourths of all reports. Approximately 40%
of detections were from respiratory specimens, and 70% of
reported infections occurred during the enterovirus season
(Table 3).
Human Parechoviruses 1 and 2
Clinical manifestations of human parechovirus infections
include aseptic meningitis, encephalomyelitis, acute flaccid
paralysis, and neonatal sepsis with necrotizing enterocolitis
(14,120). A nursery outbreak of human parechovirus 1 infec-
tion has been described (120). During 1970–2005, human
parechovirus 1 (formerly echovirus 22) accounted for 880
detections (1.8% of reports with known serotype) (Table 2).
Although the virus was among the 15 most common sero-
types during 26 of 36 years, its highest rank was eighth (1977,
1982, 1985, and 1996), consistent with the endemic pattern
of circulation. Overall level of reported activity was highest
throughout the 1980s and declined to the current low level
after 1996 (Figure 22). Approximately 95% of human
parechovirus 1 detections were reported in children aged
<5 years and 73% in children aged <1 year. The most com-
monly reported source was respiratory specimens. The major-
ity (62.9%) of infections occurred during the summer-fall
season, but the seasonality was not as prominent as for the
majority of enteroviruses. Human parechovirus 1 had the high-
est reported proportion of fatal outcomes (10.9%) compared
with all other serotypes, and persons infected with this virus
were at a significantly higher risk for death than those
infected with other serotypes (OR = 3.7; CI = 1.7–7.6).
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Human parechovirus 2 (formerly echovirus 23) was rarely
reported, and its characteristics resembled those for human
parechovirus 1 (Tables 2 and 3).
Other Serotypes
Other coxsackie A viruses were rarely reported, and each
accounted for a very small proportion of reports; reports of
these viruses became extremely rare after the mid-1990s.
The exception from this pattern was coxsackievirus A1, with
15 reports in 2004 (compared with nine during 1970–2003).
These reports were associated with an outbreak of aseptic
meningitis caused by coxsackievirus A1 that was identified by
the CDC Enterovirus Laboratory using molecular methods.
Reports of coxsackievirus B6 were at a steady low level through-
out the study period. Other echovirus serotypes
together accounted for approximately 10% of all reports with
known serotype, with individual serotype contribution rang-
ing from <0.1% to 1.4%. Reports of several of these
serotypes remained stable throughout the study period, and
reports of echoviruses 14, 16, 17, 19, 26, 27, 29, 31, and 32
became very rare or absent during the 1990s and 2000s. Only
one case of enterovirus 70 was reported. This virus is usually
associated with large scale outbreaks of acute hemorrhagic con-
junctivitis in tropical countries, but importations into the
United States by travelers from affected areas have been
reported (121). For the entire study period, no cases of
coxsackieviruses A19 and A22, enterovirus 69, and recently
identified enteroviruses numbered 73 and higher were
reported.
Discussion
Serotype-based enterovirus surveillance provides a mecha-
nism for determining patterns of enterovirus circulation and
for identifying predominant serotypes for a given season.
Monitoring circulating enteroviruses is important because
individual serotypes can be associated with different clinical
manifestations and outcomes and have different temporal
patterns of circulation. Changes in predominant serotypes can
be accompanied by large-scale outbreaks of enteroviral ill-
nesses. Although predominant serotypes change over time, the
analysis of long-term surveillance data identified a core group
of enteroviruses that consistently appear among those most
commonly reported. These common serotypes probably
determine, to a substantial degree, the overall impact of
enterovirus infections in terms of associated disease burden.
In addition, the availability of surveillance data for the period
spanning nearly four decades allowed identification of long-
term temporal trends for individual serotypes missed in
reports with shorter observation periods.
Although the reasons for differences in long-term patterns
of individual serotypes are unclear, both the agent and host
factors probably affect enterovirus circulation. For many
serotypes (e.g., echoviruses 13 and 30 and coxsackievirus B5),
increases in activity have been associated with the emergence
of new genetic lineages, which often replace the previously
circulating ones (46,48,55,98); for other enteroviruses, mul-
tiple lineages might co-exist (122). Reemergence of an old
epidemic genotype after being replaced for several years by
another genotype also has been described (123). Population
immunity to a particular serotype determines, to a great degree,
the potential extent of the virus spread and disease. Accumu-
lation of a susceptible population, especially in younger
cohorts, during the years of the quiescence of the virus prob-
ably is a contributing factor to periodic increases in circula-
tion levels of enteroviruses with a regular epidemic pattern.
NESS provided data to determine descriptive epidemiologic
characteristics for enteroviruses as a group and for individual
serotypes, including relatively rare ones. The analysis in this
report demonstrated a higher risk for death associated with
coxsackievirus B4 and human parechovirus 1 compared with
detections of other enterovirus serotypes and a lower risk for
fatal outcome for those infected with echovirus 9, which have
implications for patient prognosis. Associations of other sero-
types with an increased or reduced risk for fatal outcome might
have been missed because outcome was reported in only a
small proportion of cases. The factors contributing to the
differences in the risk for fatal outcome are unknown.
Different serotypes were detected more frequently in cer-
tain types of specimens, reflecting variations by serotype in
typical clinical presentations. For example, echoviruses 9 and
30, the viruses commonly associated with aseptic meningitis
outbreaks, were mostly detected in CSF, and coxsackievirus
A16, the leading cause of hand, foot, and mouth disease in
the United States, was mostly commonly detected in speci-
mens other than CSF, stool, or respiratory swabs.
The summer-fall seasonality of enterovirus infections in tem-
perate climates has been well established (1,2,28). The more
pronounced seasonality for enterovirus detection in CSF
compared with other specimens probably reflects the highly
seasonal occurrence of aseptic meningitis, the most common
CNS illness associated with enteroviruses, and the heightened
index of suspicion for patients with neurologic symptoms dur-
ing the traditional enteroviral season. Male predominance
among patients with enterovirus infections (1,2) was only
present among persons aged <20 years. The lack of this asso-
ciation for adults aged >20 years probably resulted from greater
exposure of female caregivers to young children who are the
primary source of exposure within a household.
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The decline in the proportion of reports with known sero-
type after the mid-1990s was probably caused by decreasing
availability of typing reagents and concerns over cost and clini-
cal utility of enterovirus typing. The increase noted after 2001
is associated with increasing use of molecular typing methods
by reporting laboratories.
Strengths and Limitations
By allowing identification of temporal trends and patterns
of circulation of individual enterovirus serotypes and provid-
ing information on circulating serotypes, enterovirus surveil-
lance becomes a useful instrument from both the public health
and clinical perspectives. Although NESS is not designed for
real-time outbreak detection, the information from this sur-
veillance system allows timely identification of predominant
serotypes and helps guide outbreak investigations. The increase
in reports of echoviruses 13 and 18 noted by NESS early in
the 2001 enterovirus season (124) helped state and local health
departments identify these serotypes as the major agents asso-
ciated with aseptic meningitis outbreaks that year (98). Rec-
ognition of the outbreak serotypes was particularly important
because specific monoclonal antibodies for echoviruses 13 and
18 are not commercially available, so indirect immunofluo-
rescence could not be used for typing to differentiate out-
break cases from sporadic enterovirus infections. Knowledge
of the outbreak serotypes encouraged laboratories that used
exclusively monoclonal antibodies for typing to refer isolates
to a reference laboratory capable of typing by other methods.
Identification of the outbreak serotypes also helped confirm
enteroviruses as the predominant etiology of aseptic meningi-
tis during a West Nile virus avian epizootic (125). Similarly,
the NESS data indicating an increase in echoviruses 9 and 30
helped focus the investigation of aseptic meningitis outbreaks
in 2003 on these serotypes (22).
Enterovirus surveillance data can be helpful in identifying
targets for diagnostic assay development. Serotype-specific
PCR assays for echoviruses 13 and 18 rapidly developed by
the CDC Enterovirus Laboratory in 2001 in response to the
increases in their reports documented by NESS (124) pro-
vided a useful tool for outbreak investigations, allowing timely
detection of epidemic serotypes (98). The information about
circulating enterovirus serotypes also is important for devel-
opment of antiviral compounds against enteroviruses because
different serotypes have differential sensitivity to at least one
candidate antienterovirus drug (pleconaril) (126). In addition,
NESS data are useful for interpreting trends in enteroviral
illnesses and for studies of enterovirus associations with spe-
cific diseases. For example, the increases in nationwide rates
for viral meningitis-associated hospitalizations in the United
States occurred when certain serotypes predominated (e.g.,
echovirus 30 in 1991 and 1998 and echovirus 9 in 1999);
lower rates of hospitalization were observed during the years
when a predominance of certain other serotypes (e.g., echovi-
rus 11 in 1988) was observed (28).
Although this report is limited to nonpolio enteroviruses,
monitoring poliovirus detection is an important aspect of
NESS. Because of the elimination of indigenous wild poliovi-
ruses in the Americas and cessation of oral poliovirus vaccine
(OPV) use (20,21), no poliovirus reservoir exists in the United
States, except for few immunodeficient persons with persis-
tent poliovirus infection, and poliovirus reports to NESS most
likely reflect importations. Only one poliovirus (vaccine type)
was reported to NESS in 2000, and no other polioviruses were
reported until 2005. In 2005, vaccine-derived poliovirus type
1 circulation in a group objecting to vaccination was reported
in Minnesota (127). This episode underscores the potential
for poliovirus importation as long as wild polioviruses con-
tinue to circulate in certain parts of the world and OPV con-
tinues to be used by the majority of countries. As a result,
NESS will remain a supplemental means of polio surveillance
in the United States until the global eradication of wild polio-
viruses and the cessation of OPV use.
NESS is subject to at least three limitations. First, enterovi-
ruses that commonly infect younger patients or that are asso-
ciated with more severe illnesses might be overrepresented in
NESS because clinical specimens from young children and
more severely ill patients are submitted for testing more fre-
quently. A potential explanation for a testing bias is that speci-
mens might be more frequently submitted for enterovirus
testing among young or more severely ill patients, in whom a
specific diagnosis is considered more urgent, compared with
older patients with milder disease, in whom ruling out bacte-
rial meningitis might be a sufficient diagnosis. The extent of
this testing bias is difficult to measure because population-
based data on the incidence of enterovirus infections are not
easily available. Aseptic meningitis is the most common
severe clinical manifestation associated with enterovirus
infection. In one study, population-based estimates of per-
sons hospitalized with viral meningitis in the United States
based on the National Hospital Discharge Survey (NHDS)
data (28) were compared with NESS data. The proportion of
infants aged <1 year among patients reported to NESS was
approximately double that from the NHDS study (44.2%
and 23.5%, respectively). The proportion of fatal outcomes
was approximately eightfold higher among patients reported
to NESS (3.3%) than among patients hospitalized with viral
meningitis (0.4%) (28).
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Second, because of the voluntary and passive nature of
reporting to NESS, the small number of reports from certain
states, and the absence of reports from some others, these
results might not be representative of enterovirus circulation
in the entire United States. The annual numbers of reports to
NESS varied considerably. Consistent with a previous report
(3), this year-to-year variability is, in part, the function of
variability in the number of reporting laboratories. A general
decline in use of viral culture because of its high cost, labor
intensiveness, and modest clinical utility and the reduced avail-
ability of typing reagents along with the introduction of
panenterovirus PCR assays were additional factors leading to
the relative decline in enterovirus surveillance reports observed
during the 1990s. The increased number of participating sites
since 2000 and the widest ever geographic coverage achieved
by NESS in 2005 are encouraging and might be attributable
to simplified methods for data submission. However, the
majority of state public health laboratories did not report to
NESS during the last few years, and the available information
for these states was received indirectly through private labora-
tories and the CDC Enterovirus Laboratory testing specimens
of patients from these states and reporting to NESS. Because
of the higher cost of private laboratory testing, reported
enterovirus activity in states from these sources is
underrepresented in NESS. Efforts to increase laboratory par-
ticipation in NESS should continue to allow for more com-
plete and accurate surveillance for enteroviruses in the United
States.
Finally, serotype distribution in NESS is biased because of
the low likelihood of serotypes being reported that cannot be
readily detected by available methods. For example, coxsackie
A viruses are most likely underrepresented in NESS because
many of these viruses grow poorly in cell culture. Tradition-
ally, the primary method for their detection has been isola-
tion by intracerebral inoculation of suckling mice. The use of
this technique has declined during the preceding 10–15 years,
concurrent with the overall decline in coxsackie A virus
reports to NESS. The sharp increase in coxsackievirus A1
reports in 2003 with the use of molecular typing suggests that
as molecular methods are adopted more widely, more accu-
rate information on coxsackie A virus epidemiology will
become available.
Public Health Actions
Concerns about declining laboratory participation in NESS
throughout the 1990s led to efforts to update the reporting
system and to make it more user-friendly. These efforts, initi-
ated in the early 2000s, included simplification of reporting
forms and transition to electronic reporting and resulted in a
substantial increase in reporting compared with the late 1990s.
Further improvements in the timeliness of feedback could
provide additional incentives to public health laboratories to
participate in NESS. A NESS website is being developed that
will allow access to historic national and state enterovirus sur-
veillance data and information on circulating serotypes.
Developing a system for web-based data entry will further
streamline the process of reporting to NESS and allow for
improved feedback to stakeholders. The system will have suf-
ficient built-in flexibility to adapt to changing laboratory prac-
tices and evolving taxonomy. Reporting of newly identified
enteroviruses and other picornaviruses could be incorporated as
needed. The assistance provided by CDC’s Enterovirus Labo-
ratory to state public health laboratories in implementing
molecular methods of typing and efforts to increase laboratory
participation in NESS should be continued to allow for more
complete and accurate surveillance for enteroviruses in the
United States.
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FIGURE 1. Number of enterovirus reports with known or
unknown serotype and number of states reporting
enteroviruses, by year — National Enterovirus Surveillance
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FIGURE 2. Percentage of enterovirus reports, by month of























































FIGURE 3. Number and percentage of enterovirus detection
reports with fatal outcomes, by age group — National
Enterovirus Surveillance System, United States, 1983–1998
FIGURE 4. Number of reported echovirus 9 detections, by
year and percentage of all reports — National Enterovirus
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FIGURE 5. Number of reported echovirus 11 detections, by
year and percentage of all reports — National Enterovirus
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FIGURE 6. Number of reported echovirus 30 detections, by
year and percentage of all reports — National Enterovirus
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FIGURE 7. Number of reported coxsackievirus B5 detections,
by year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 8. Number of reported echovirus 6 detections, by
year and percentage of all reports — National Enterovirus
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FIGURE 9. Number of reported coxsackievirus B2 detections,
by year and pecentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 10. Number of reported coxsackievirus A9
detections, by year and percentage of all reports — National
Enterovirus Surveillance System, United States, 1970–2005
FIGURE 11. Number of reported echovirus 4 detections, by
year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 12. Number of reported coxsackievirus B4
detections, by year and percentage of all reports — National
Enterovirus Surveillance System, United States, 1970–2005
Vol. 55 / SS-8 Surveillance Summaries 19
FIGURE 13. Number of reported echovirus 7 detections, by
year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 14. Number of reported coxsackievirus B3
detections, by year and percentage of all reports — National
Enterovirus Surveillance System, United States, 1970–2005
FIGURE 15. Number of reported echovirus 18 detections, by
year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 16. Number of reported coxsackievirus B1
detections, by year and percentage of all reports — National
Enterovirus Surveillance System, United States, 1970–2005
FIGURE 17. Number of reported echovirus 3 detections, by
year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 18. Number of reported echovirus 5 detections, by
year and percentage of all reports — National Enterovirus
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FIGURE 19. Number of reported echovirus 13 detections, by
year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 20. Number of reported coxsackievirus A16
detections, by year and percentage of all reports — National
Enterovirus Surveillance System, United States, 1970–2005
FIGURE 21. Number of reported enterovirus 71 detections,
by year and percentage of all reports — National Enterovirus
Surveillance System, United States, 1970–2005
FIGURE 22. Number of reported human parechovirus 1
detections, by year and percentage of all reports — National
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